Drugs / L-ASP
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06361329 Comparator | Apr 2024 → Mar 2026 overdue | early T cell progenitor acute lymphoblastic leukemia | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-ASP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06361329 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT06361329 ↗ |